Erasca | Investor Presentation Deck | 56 slides · page 45 of 56
The slide uses a structured comparison between preclinical and clinical assets, with a specific callout for the lead asset (Naporafenib).
Pitch deck · competitive_analysis · compare_peers · dense density
Slide locked Sign in to view
Slide schematic 6/6
disclaimer 1/1 framework 1/1 list 3/3 title 1/1
Components 6
disclaimer instance bullet bullet bullet headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 1